Navigation Links
Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
Date:8/29/2013

but are not limited to, risk that elagolix will not proceed to later stage clinical trials for uterine fibroids; risk that the elagolix clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of uterine fibroids; risk that elagolix uterine fibroid Phase III clinical trials will be delayed or not successfully initiated; risk that elagolix Phase III clinical trials will fail to demonstrate that elagolix is safe and effective for the treatment of endometriosis; risk associated with the Company's dependence on corporate collaborators for clinical development, commercial manufacturing and marketing and sales activities. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2012 and report on Form 10-Q for the quarter ended June 30, 2013. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.


'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
2. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
3. Neurocrine Biosciences Reports First Quarter 2013 Results
4. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
5. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
6. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
7. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
8. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
9. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
10. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
11. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  Amerigen Pharmaceuticals Ltd. announces ... Ltd., has received Chinese FDA (CFDA) approval and ... Tablets into the China ... and distribution agreement with Sinochem Jiangsu Pharmaceutical Co., ... US FDA approved and China CFDA certified oral ...
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... -- Trovagene, Inc. (NASDAQ:   TROV), a developer of ... clinical studies will be presented at the 29th International ... for the detection of high risk strains of Human ... place in Seattle from August ... new U.S. patent was issued earlier this year for ...
Breaking Medicine Technology:Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3
... , , , ... Exposure of Type I Diabetes Patients to Oramed,s Oral,Insulin and of a First-in-Humans Study With ... Oramed Pharmaceuticals, ... of the,American Diabetes Association currently being held in Orlando, Florida . Dr., Miriam Kidron ...
... WASHINGTON , June 28 Harris Corporation (NYSE: ... Inc., is helping to improve the quality of military patient ... Information Exchange (BHIE) interface.  The exchange is a health enterprise ... the Department of Veterans Affairs (VA) to securely share patient ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association 2Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association 3Harris Corporation Leverages CONNECT Solution to Enhance Patient Information Exchange Between DoD and VA 2
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... Open Tennis Championship tickets in NYC. In just a ... USTA Billie Jean King Tennis Center. The event was originally founded ... the 2013 event, Rafael Nadal was forced to withdrawal from the ... of the 2014 women’s tournament and will return to New York ...
(Date:8/20/2014)... Line: A study in Australia examined patient and ... (a marker of tumor cell growth) in an ... cancer in patients. , Author: ... Victoria, Australia, and colleagues. , Background: The ... cell division) has been connected with prognosis and ...
(Date:8/20/2014)... Opinion: The time to deploy Ebola vaccines is now, ... vaccines is now, according to a commentary being published ... Medicine . The authors from Yale School of ... geographic dissemination of the current Ebola outbreak represent a ... under current efforts. Several Ebola vaccines have been developed ...
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- Loss of brain ... explain why many seniors have trouble falling and staying ... sleep disruption can be especially severe and often results ... The investigators analyzed data from the Rush Memory ... enrolled at age 65 and are being followed until ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 The ... firm Perkins Eastman is pleased to announce ... services in China and the surrounding ... Principal Richard Sprow AIA has relocated to ... 40-year career in healthcare planning and design and to ...
Breaking Medicine News(10 mins):Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 2Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 3Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 4Health News:2014 U.S. Open Tennis Tickets: Ticket Down Slashes Ticket Prices on All US Open Tennis Championship Sessions in New York at Arthur Ashe Stadium 5Health News:Patient, tumor characteristics for high-mitotic rate melanoma 2Health News:News from Annals of Internal Medicine 2Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3
... of it kind to establish a link between sleep and ... have higher insulin resistance, and a harder time controlling the ... Diabetes Care , suggest that poor sleep may contribute ... quality in people with diabetes was associated with worse control ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... supplements and teas for infants is a surprisingly common practice, ... not be safe for babies. The study, conducted ... 10 percent of babies are given botanical supplements or teas ...
... News) -- Infants who aren,t breast-fed may experience long-term health ... body composition (fat mass vs. lean body mass) and blood ... for the first four months of life, while infants in ... formula: a lower-protein formula with 1.8 grams (g) of protein ...
... DENVER, CO, MAY 2, 2011 Two scientists who ... been chosen to receive the 2011 March of Dimes ... OBE, DSc, FRS, professor of Human Genetics, Southampton University ... Laboratory, Salisbury, England and David C. Page, MD, director, ...
... ROCHESTER, Minn. -- By all counts, the 54-year-old man ... Minnesota would likely have died. He,d suffered a heart ... and a series of shocks with a defibrillator, the ... this particular instance of cardiac arrest ( http://www.mayoclinic.org/heart-attack/ ), ...
... May 2 (HealthDay News) -- Obese pregnant women may have ... new research suggests. Researchers tested the blood of 30 ... and had a body-mass index (BMI) of more than 30 ... of 20 to 25. Obese women had fewer immune ...
Cached Medicine News:Health News:Insomnia linked to high insulin resistance in diabetics 2Health News:Study Questions Giving Babies Botanical Supplements, Teas 2Health News:Study Questions Giving Babies Botanical Supplements, Teas 3Health News:Breast-feeding May Influence Long-Term Health: Study 2Health News:Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes 2
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: